CompletedPhase 2ACTRN12605000105640

A phase-II study of a modified Hyper-CVAD frontline therapy for patients with poor prognosis diffuse large B-cell and peripheral T-cell non-Hodgkins lymphoma to evaluate safety and improve remission rate.

Sponsor

Australasian Leukaemia and Lymphoma Group

Enrollment

70 participants

Start Date

Sep 7, 2001

Study Type

Interventional

Conditions

Histologically aggressive non-Hodgkins lymphoma B- or T-cell lineage with a poor prognosis (International Prognostic Factors Index score of 2 or greater).

Eligibility

Sex: Both males and femalesMin Age: 15 YearssMax Age: 70 Yearss

Plain Language Summary

Simplified for easier understanding

This is a clinical study looking at treatments for acute lymphoblastic leukemia. It is open to aged 15 to 70 who have been diagnosed with acute lymphoblastic leukemia. Participation typically involves regular medical visits, tests, and following a specific treatment plan.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

A dose and time intensive chemotherapy regimen comprising alternating A and B cycles. A cycles comprise hyperfractionate cyclophosphamide, vincristine, doxorubicin and dexamethasone, and B cycles comprise high-dose methotrexate and high-dose cytosine arabinoside. A total of 6 cycles are to be delivered.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000105640